Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 16/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566350 | 1.00 | GPR183 (0.41) | GPR183KCNH2MAOBNR1H4MAPT | |
| SCHEMBL5558380 | 0.83 | GPR183 (0.43) | GPR183KCNH2MAOB | |
| SCHEMBL5558384 | 0.83 | GPR183 (0.43) | GPR183KCNH2MAOB | |
| SCHEMBL16398593 | 0.78 | UTRN (0.42) | NR1H4MAPTCYP1A2 | |
| SCHEMBL740362 | 0.77 | ADORA3 (0.49) | MAPTCYP1A2 | |
| SCHEMBL740361 | 0.77 | ADORA3 (0.49) | MAPTCYP1A2 | |
| SCHEMBL5563033 | 0.77 | ERBB2 (0.50) | MAOBMAPT | |
| SCHEMBL5563029 | 0.77 | ERBB2 (0.50) | MAOBMAPT | |
| SCHEMBL31434775 | 0.77 | NR1H4 (0.38) | NR1H4MAPTCYP1A2 | |
| SCHEMBL5563629 | 0.76 | POLB (0.44) | MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622896-B1 | NOVEL ANILINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | EP | disclosed |
| US-7205326-B2 | Aniline derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1622896-A1 | NOVEL ANILINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| US-20040254217-A1 | Aniline derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004096796-A1 | NOVEL ANILINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254217-A1 | Aniline derivatives, their manufacture and use as pharmaceutical agents | ERBB2, EGFR, ERBB3 | GPR183 187/4885KCNH2 4334/4885MAOB 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.